PROMIS NEUROSCIENCES INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PROMIS NEUROSCIENCES INC. (PMN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2023-11-14
- PROMIS NEUROSCIENCES INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 0.00 shares.
- PROMIS NEUROSCIENCES INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 208.33K shares.
- PROMIS NEUROSCIENCES INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 360.00K shares, a 82.47% increase from fiscal 2021.
- PROMIS NEUROSCIENCES INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 197.29K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 0.00 shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | 208.33K shares derived: sum of 2 quarters · filed 2023-03-08 | 360.00K shares 10-K · filed 2023-03-08 | |
| 2022-09-30 | 208.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 360.00K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 151.67K shares 10-Q · filed 2022-08-12 | |||
| 2021-12-31 | 197.29K shares 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |